Loading clinical trials...
Loading clinical trials...
This randomized, double-blind, placebo-controlled Phase II study is designed to evaluate the efficacy, safety, and tolerability of ASC30 oral tablets formulation in participants with Type 2 Diabetes M...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Ascletis Pharma (China) Co., Limited
NCT07314684 · T2DM (Type 2 Diabetes Mellitus)
NCT06293417 · T2DM (Type 2 Diabetes Mellitus), Dyslipidemias
NCT07172997 · MASLD, T2DM (Type 2 Diabetes Mellitus), and more
NCT06733805 · Clinical Audit, Quality Improvement, and more
NCT07537088 · T2DM (Type 2 Diabetes Mellitus), CKD - Chronic Kidney Disease
Ascletis Clinical Site
Riverside, California
Ascletis Clinical Site
San Jose, California
Ascletis Clinical Site
Denver, Colorado
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions